Ozempic and Wegovy Lawsuit Lawyer
GET YOUR FREE CASE REVIEW
"*" indicates required fields
By clicking the Submit button, you consent to being contacted by Harding Mazzotti, LLP at the number and/or email provided, and consent to receiving SMS/text messages. Message and Data Rates may apply. You can STOP messaging by sending STOP and get more help by sending HELP. You acknowledge that submitting this form and the information contained therein does not establish an attorney client relationship, and therefore, you will not rely upon this information as legal advice. By submitting this form, you understand that any information received in response to this questionnaire is general information for which there will be no charge.
Content Reviewed by:
- Date Last Updated:
On This Page
About Ozempic and Wegovy
The drug Ozempic was developed by Novo Nordisk and approved to help control high blood sugar in patients with Type 2 diabetes in 2017. The drug includes the ingredient semaglutide, a glucagon-like peptide-1. Glucagon-like peptide 1 encourages the release of insulin from the pancreatic beta cells, increases the volume of pancreatic beta cells, and reduces the release of glucagon. It also slows the passage of food through the stomach. Soon after Ozempic entered the market, it was observed that the drug caused appetite suppression often resulting in weight loss. With this knowledge manufacturer Novo Nordisk then developed Wegovy, a higher dose version of Ozempic, which was approved by the FDA in 2021 to treat patients with weight gain and obesity. Both Ozempic and Wegovy are administered by the patient via subcutaneous injection.
Gastroparesis and Intestinal Blockage Linked to Ozempic and Wegovy
In 2023, the FDA reported that complaints submitted through the FDA Adverse Event Reporting System (FAERS) point to potential safety issues with these medications. This includes the life-threatening risk of intestinal obstruction.
Intestinal obstructions are more likely to occur in people taking semaglutide medications like Ozempic and Wegovy , according to published studies. Signs and symptoms of intestinal blockage (also known as an obstruction) may include:
- Constipation
- Abdominal pain, cramping and swelling
- Inability to pass gas
- Vomiting
- Loud stomach sounds
Patients with gastroparesis, often known as stomach paralysis, have also recently been reported by doctors. Gastroparesis causes food to remain in the stomach for an excessive amount of time, or for the stomach to not empty properly, because the nerves and muscles have been stopped from functioning normally. The following are typical signs of gastroparesis:
- Acid Reflux/Indigestion
- Nausea
- Vomiting
- Bloated stomach
- Feeling full very quickly or after eating very little
- Abdominal pain
- Loss of appetite
- Malnutrition
Lawsuits allege that Novo Nordisk neglected to warn of intestinal blockages and stomach paralysis.
Ozempic and Wegovy Updates
Ozempic and Wegovy Linked To Condition That Causes Blindness
Update, April 2025: Another study connected GLP-1 use to vision loss based on FDA complaints. However, as of May 5, 2025, no warnings of this connection are currently listed on GLP-1 RA product labels.
Update, February 2025: A JAMA Ophthalmology study found two new eye complications linked to GLP-1 RAs: bilateral papillitis and paracentral acute middle maculopathy. Both conditions are similar to NAION in that they involve the optic nerve, but unlike NAION, they are treatable and reversible.
Update, December 2024: Danish researchers published a five-year longitudinal study that confirmed earlier findings linking semaglutide to an increased risk of vision loss. According to the study, use of the active ingredient commonly found in once-weekly Ozempic and Wegovy more than doubled the risk of losing vision.
Update, July 2024: A study has linked use of semaglutide-containing drugs like Ozempic and Wegovy to a serious eye condition which can cause irreversible vision loss. Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition that affects the optic nerve. In individuals with NAION, blood flow to the optic nerve gets reduced or blocked, leading to sudden vision loss. The researchers found that patients treating diabetes with semaglutide at four times higher risk for developing NAION. Patients using semaglutide for weight loss had a seven-times higher risk of developing NAION.
Do you have a case? Get your free consultation now.
You can call us at 1-800-LAW1010 or fill out a form. Even if you’re unsure if you have a case, our team is here to help you discuss your legal options at no charge.
Contact a Wegovy and Ozempic Lawyer Today
If you or a loved one used the drugs Wegovy or Ozempic and experienced gastroparesis, intestinal obstruction, deep vein thrombosis, pulmonary embolism, muscle wasting, malnutrition, or non-arteritic anterior ischemic optic neuropathy, contact the Ozempic and Wegovy injury lawyers at Harding Mazzotti, LLP today for a free case evaluation. Click, Chat, or call 1800LAW1010 24/7 for a free consultation.
injured in an accident?
Get your free case review today
After filling out a form, our team will be in touch to schedule a free consultation to discuss your case.
For a quick response, call us at (844) 446-1044
